Isolated limb perfusion in the treatment of soft tissue sarcoma: evolution, characteristics, prospects of application

It performed the analysis of literature data on development of isolated limb perfusion (ILP) in the treatment of soft tissue sarcomas (STS), its clinical efficacy and safety. The historical aspects of the method introduction into clinical practice are considered. It is noted that for more than two decades the method has been used for locally advanced limb sarcomas, unifocal tumors localized in the neurovascular bundle with invasion into the bundle or bone, tumor recurrence in previously irradiated areas without the possibility of radical resection. The technique of performing the method, drugs (melphalan and tumor necrosis factor-α) and their modes of application are described.

It was noted that systemic toxicity during ILP is directly associated with the volume of the drug entering the systemic circulation, as a rule, the value of this indicator is less than 3–4 %. Discussion issues of the criteria for the effectiveness of STS treatment are considered, it is indicated that the main result of ILP is used by most authors the criterion of the extremity rescue frequency, its value ranges from 72 to 96 %. Survival without signs of local recurrence within 5 years after ILP with melphalan/tumor necrosis factor-αand tumor resection is from 73 to 87 %. The tasks of improving ILP are described, including the need to search for combined treatment regimens for local and systemic therapy in patients who undergo this treatment. Promising directions are the improvement of forecasting tools and the creation of innovative drugs that can be used in ILP, which will contribute to a higher clinical efficacy and safety of the method in the treatment of STS.

1. Teras J., Mägi A., Teras M. et al. Soft Tissue Cancer Management: Isolated Limb Infusion for Sarcoma. Visc Med 2019;35(6):373−9. DOI: 10.1159/000495888.

2. Hohenberger P., Wysocki W.M. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose? Oncologist 2008;13:175−86. DOI: 10.1634/theoncologist.2007-0165.

3. Jiménez Herevia A.E., Tavares de la Paz L.A., Hinojosa Ugarte D., Nieves Condoy J. Isolated Limb Perfusion on Nonmelanoma Skin Cancer for Limb Salvage: A Series of Four Cases. Cureus 2020;12(8):e9998. DOI: 10.7759/cureus.9998.

4. Rosenberg S.A., Tepper J., Glatstein E. et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196(3):305−15. DOI: 10.1097/00000658-198209000-00009.

5. Eggermont A.M., Schraffordt Koops H., Klausner J.M. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756−64. DOI: 10.1097/00000658-199612000-00011.

6. Creech O., Krementz E.T., Ryan R.F., Winblad J.N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616−32. DOI: 10.1097/00000658-195810000-00009.

7. Klopp C.T., Alford T.C., Bateman J. et al. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 1950;132:811−32. DOI: 10.1097/00000658-195010000-00018.

8. Lejeune F.J., Kroon B.B., Di Filippo F. et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001;10:821−32.

9. Grueneisen J., Schaarschmidt B., Demircioglu A. et al. 18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. J Nucl Med 2019;60(11):1537−42. DOI: 10.2967/jnumed.119.226761.

10. Martin-Tellez K.S., van Houdt W.J., van Coevorden F. et al. Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 2020;88:102058. DOI: 10.1016/j.ctrv.2020.102058.

11. Rastrelli M., Campana L.G., Valpione S. et al. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: a 24-year single-centre experience. Int J Hyperthermia 2016;32:165–72. DOI: 10.3109/02656736.2015.1101170.

12. Wray C.J., Benjamin R.S., Hunt K.K. et al. Isolated limb perfusion for unresectable extremity sarcoma: results of 2 singleinstitution phase 2 trials. Cancer 2011;117:3235−41. DOI: 10.1002/cncr.25850.

13. Seinen J.M., Hoekstra H.J. Isolated limb perfusion of soft tissue sarcomas: a comprehensive review of literature. Cancer Treat Rev 2013;39:569−77. DOI: 10.1016/j.ctrv.2012.10.005.

14. Hansson J., Lewensohn R., Ringborg U., Nilsson B. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to druginduced cytotoxicity in human melanoma cells. Cancer Res 1987;47:2631−7.

15. Roberts M.S., Wu Z.Y., Siebert G.A. et al. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001;11:611−8. DOI: 10.1097/00008390-200112000-00007.

16. Eggermont A.M., ten Hagen T.L. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001;3:359−67. DOI: 10.1007/s11912-001-0090-8.

17. Nachmany I., Subhi A., Meller I. et al. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. Eur J Surg Oncol 2009;35:209−14. DOI: 10.1016/j.ejso.2008.01.007.

18. Pennacchioli E., Deraco M., Mariani L. et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 2007;14:553−9. DOI: 10.1245/s10434-006-9251-1.

19. Sijens P.E., Eggermont A.M., van Dijk P.V., Oudkerk M. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed 1995;8:215−24. DOI: 10.1002/nbm.1940080506.

20. Hoekstra H.J., van Ginkel R.J. Hyperthermic isolated limb perfusion in the management of extremity sarcoma. Curr Opin Oncol 2003;15:300−3. DOI: 10.1097/00001622-200307000-00004.

21. Bonvalot S., Laplanche A., Lejeune F. et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 2005;16:1061−8. DOI: 10.1093/annonc/mdi229.

22. Cavaliere R., Ciocatto E.C., Giovanella B.C. et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967;20:1351−81. DOI: 10.1002/1097-0142(196709)20:9<1351:: aid-cncr2820200902>3.0

23. Eggermont A.M., de Wilt J.H., ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429−37. DOI: 10.1016/s1470-2045(03)01141-0.

24. Pai M.P. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012;32:856−68. DOI: 10.1002/j.1875-9114.2012.01108.x.

25. Wieberdink J., Benckhuysen C., Braat R.P. et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905−10. DOI: 10.1016/0277-5379(82)90235-8.

26. Podleska L.E., Poeppel T., Herbrik M. et al. Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation. World J Surg Oncol 2014;12:81. DOI: 10.1186/1477-7819-12-81.

27. Cecchin D., Negri A., Frigo A.C. et al. Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared. Eur J Surg Oncol 2016;42:1898−1905. DOI: 10.1016/j.ejso.2016.02.250.

28. Scott R.N., Kerr D.J., Blackie R. et al. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992;66:159−66. DOI: 10.1038/bjc.1992.235.

29. Hoven-Gondrie M.L., Bastiaannet E., van Ginkel R.J. et al. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. J Surg Oncol 2011;103:648−55. DOI: 10.1002/jso.21885.

30. Харатишвили Т.К., Петроченко Н.С., Бохян Б.Ю. Эффективность и безопасность метода изолированной перфузии конечностей с гипертермией у больных с саркома-ми мягких тканей. Саркомы костей, мягких тканей и опухоли кожи 2016;4:32−9.

31. Vrouenraets B.C., Nieweg O.E., Kroon B.B. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319−28. DOI: 10.1002/bjs.1800831004.31.

32. Наркевич Б.Я., Ширяев С.В., Лагутина И.В. и др. Контроль химиотерапевтической перфузии изолированной конечности у боль-ных меланомой или саркомой мягких тканей. Онкологический журнал: лучевая диагностика, лучевая терапия 2019;2(2):28−35.

33. Moller M.G., Lewis J.M., Dessureault S., Zager J.S. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008;24:275−89. DOI: 10.1080/02656730701805520.

34. Vaynrub M., Taheri N., Ahlmann E.R. et al. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma. J Surg Oncol 2015;111:152−7. DOI: 10.1002/jso.23775.

35. Grabellus F., Stylianou E., Umutlu L. et al. Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. Ann Surg Oncol 2012;19:3375−85. DOI: 10.1245/s10434-012-2408-1.

36. Wardelmann E., Haas R.L., Bovée J.V. et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC−STBSG) recommendations for pathological examination and reporting. Eur J Cancer 2016;53:84−95. DOI: 10.1016/j.ejca.2015.09.021.

37. Stevenson M.G., Hoekstra H.J., Song W. et al. Histopathological tumor response following neoadjuvant hyperthermic isolated limb perfusion in extremity soft tissue sarcomas: Evaluation of the EORTC−STBSG response score. Eur J Surg Oncol 2018;44(9):1406−11. DOI: 10.1016/j.ejso.2018.05.011.

38. Neuwirth M.G., Song Y., Sinnamon A.J. et al. Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. Ann Surg Oncol 2017;24:3803−10. DOI: 10.1245/s10434-017-6109-7.

39. Trabulsi N.H., Patakfalvi L., Nassif M.O. et al. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol 2012;106:921−8. DOI: 10.1002/jso.23200.

40. Bhangu A., Broom L., Nepogodiev D. et al. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review. Eur J Surg Oncol 2013;39:311–9. DOI: 10.1016/j.ejso.2012.12.018.

41. Deroose J.P., Eggermont A.M., van Geel A.N. et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011;29:4036−44. DOI: 10.1200/JCO.2011.35.6618.

42. Jakob J., Smith H.G., Wilkinson M.J. et al. Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. Clin Sarcoma Res 2018;8:12. DOI: 10.1186/s13569-018-0098-6.

43. Seinen J.M., Jutte P.C., Been L.B. et al. Fractures after multimodality treatment of soft tissue sarcomas with isolated limb perfusion and radiation; likely to occur and hard to heal. Eur J Surg Oncol 2018;44(9):1398−1405. DOI: 10.1016/j.ejso.2018.04.012.

44. Thijssens K.M., van Ginkel R.J., Pras E. et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol 2006;13:518−24. DOI: 10.1245/ASO.2006.02.005.

45. Huis In't Veld E.A., Grünhagen D.J., Verhoef C. et al. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. Eur J Cancer 2017;85:114−21. DOI: 10.1016/j.ejca.2017.07.023.

46. Smith H.G., Wilkinson M.J., Smith M.J.F. et al. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies. Eur J Cancer 2018;100:46−54. DOI: 10.1016/j.ejca.2018.04.014.